A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia

In brief

To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.

Key facts

Study ID

NCT01829048

Run by

Pfizer

People needed

37

Starts

2013-03-06

Expected to finish

2013-10-17

Last updated by the study team

2018-08-20

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Psychiatrically stable subjects with schizophrenia.
• Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.
• Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.

You may not qualify if…

• History of seizures or of a condition with risk of seizures.
• Subjects who have had electroconvulsive therapy within the 6 months prior to randomization.
• Pregnant or nursing females, and females of child bearing potential.

Where it is running

• California Clinical Trials Medical Group — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.